Clinical trials: Toripalimab
Non Squamous Non Small Cell Lung Cancer, EGFR Positive Non-small Cell Lung Cancer
Neoadjuvant Toripalimab for Non-squamous NSCLC With EGFR Mutation
This study was designed to investigate the efficacy and safety of neoadjuvant Toripalimab (anti-PD1) plus chemotherapy for patients with resectable II-IIIB non-squamous NSCLC harboring EGFR mutation, and to explore the potential…
- Trial name
- NCT05962021
- Testing
- Toripalimab plus Chemotherapy
- Volunteers
- 126 people
- Sponsor
- Peking University People's Hospital
Triple-Negative Breast Cancer (TNBC)
The Optimal Radioimmunotherapy Combinations for Advanced TNBC
This study aims to explore the best combination patterns of radiotherapy and immunotherapy for advanced triple-negative breast cancer (TNBC).
- Trial name
- NCT06735131
- Testing
- radiotherapy 5 Gy × 5 fractions, once a day, radiotherapy 8 Gy × 5 fractions, once a day, radiotherapy 8 Gy × 3 fractions, once every other day
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Sun Yat-sen University
CAEBV (Chronic Active Epstein-Barr Virus Infection) Syndrome, PTLDs
Clinical Study of Therapeutic Immunological Agent for EBV Lymphoproliferative Diseases
This study intends to conduct a prospective single-center open single-arm multi-dose escalation study on therapeutic immunological agent treatment in patients with Lymphoproliferative disease associated with EBV to observe the…
- Trial name
- NCT06666153
- Testing
- EBV immunological agent
- Where
- China
- Volunteers
- 27 people
- Sponsor
- West China Hospital
Huge Hepatocellular Carcinoma (HCC) (>10cm)
The Application of Locoregional Therapy Combined With Systemic Therapy in the Perioperative Period of Huge Hepatocellular Carcinoma: A Retrospective Cohort Study
This retrospective cohort study collected data of patients with huge hepatocellular carcinoma (HCC) treated between June 1, 2018, and December 31, 2023, through the hospital information system.
- Trial name
- NCT07639294
- Testing
- hepatectomy without immune checkpoint inhibitors-based adjuvant therapy, hepatectomy with immune checkpoint inhibitors-based adjuvant therapy, neoadjuvant conversion therapy followed by surgery
- Where
- China
- Volunteers
- 715 people
- Sponsor
- Tongji Hospital
Bladder Cancer
PTC-guided Neoadjuvant Therapy For Muscle-invasive Bladder Cancer
This study evaluates Patient-derived Tumor-like Cell Clusters (PTC)-guided individualized neoadjuvant therapy in patients with muscle-invasive bladder cancer who are candidates for radical cystectomy.
- Trial name
- NCT07690878
- Testing
- PTC guided individualized neoadjuvant therapy
- Where
- China
- Volunteers
- 35 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Melanoma, Lung Cance
Intensive Medicines Monitoring Study of Toripalimab Monoclonal Injection (Tuoyi) .
This study was a prospective, single-arm, multi-channel, multicenter, non-interventional real-world study to evaluate the safety and efficacy of Toripalimab injection in the treatment of unresectable or metastatic melanoma with…
- Conditions
- Melanoma, Lung Cance, Breast Cancer
- Trial name
- NCT04234620
- Testing
- Toripalimab injection
- Where
- 25 sites in China
- Volunteers
- 800 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Rhabdomyosarcoma
Exploratory Study of Personalized mRNA Vaccine in Patients With Refractory Rhabdomyosarcoma
An Exploratory Study on the Use of mRNA Tumor Vaccines in the Treatment of Refractory Rhabdomyosarcoma
- Trial name
- NCT06932861
- Testing
- personalized neoantigen mRNA vaccine
- Where
- China
- Volunteers
- 5 people
- Sponsor
- Xinxin Zhang
Soft Tissue Sarcoma
Toripalimab Combined With CAV/IE Regimen
The aim of this study was to investigate the efficacy and safety of CAV/IE chemotherapy combined with toripalimab versus CAV/IE chemotherapy alone in the treatment of patients with advanced or unresectable bone and soft tissue…
- Trial name
- NCT04589741
- Testing
- Toripalimab Combined With CAV/IE chemotherapy, CAV/IE alternate chemotherapy
- Where
- China
- Volunteers
- 134 people
- Sponsor
- Sun Yat-sen University
Sarcoma
Chidamide Combined With Toripalimab in Sarcoma
Soft tissue sarcoma is a relatively rare malignant tumor with an incidence of about 1-2/100,000. The best way to obtain evidence-based medical evidence is to participate in clinical trials with new drugs (especially targeted…
- Trial name
- NCT04025931
- Testing
- chidamide and toripalimab
- Where
- China
- Volunteers
- 73 people
- Sponsor
- Sun Yat-sen University
Muscle-invasive Bladder Urothelial Carcinoma
A Phase II Study of Toripalimab Plus RC48-ADC With Radiotherapy for Bladder Preservation in HER2-Positive Muscle-Invasive Bladder Cancer
This is a prospective, open-label, single-center, single-arm clinical study. Plans to enroll 45 MIBC patients with clinical stage T2-T4aN0M0 and HER2-positive (IHC 1+/2+/3+) status.
- Trial name
- NCT07279597
- Testing
- RC48-ADC + Toripalimab
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Tongji Hospital
SCLC, Extensive Stage, Toripalimab
Real-World Study of Toripalimab in Extensive-Stage Small Cell Lung Cancer
This is a prospective, observational, multi-center, real-world study evaluating the effectiveness and safety of Toripalimab (a PD-1 inhibitor) as first-line treatment for patients with extensive-stage small cell lung cancer…
- Trial name
- NCT07308379
- Testing
- Toripalimab
- Volunteers
- 1,200 people
- Sponsor
- Fudan University
Nasopharyngeal Cancer Recurrent
A Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Participants With Recurrent Metastatic Nasopharyngeal Cancer
This study aims to investigate toripalimab with chemotherapy in participants with nasopharyngeal cancer.
- Trial name
- TRANSPARENT (NCT06457503)
- Testing
- Toripalimab, Cisplatin, Gemcitabine
- Where
- 13 sites in United States, Canada
- Volunteers
- 100 people
- Sponsor
- Coherus Oncology, Inc.
Nasopharyngeal Cancinoma (NPC)
GP Combined with Toripalimab Versus GP Induction Chemotherapy for Advanced Childhood Nasopharyngeal Carcinoma
Nasopharyngeal carcinoma (NPC) has a low incidence rate in children, accounting for only 1-2% of pediatric tumors. However, it is prone to metastasis, and most patients are already in advanced stages at the time of diagnosis.
- Trial name
- NCT06605131
- Testing
- GP+Toripalimab+CCRT, GP+CCRT
- Where
- China
- Volunteers
- 72 people
- Sponsor
- Sun Yat-sen University
Soft Tissue Sarcomas, Undifferentiated Pleomorphic Sarcoma
Study of Anlotinib Hydrochloride and Toripalimab in Subjects With Unresectable or Metastatic Undifferentiated Pleomorphic Sarcoma
The investigators hypothesize that combination anlotinib with toripalimab will improve progression-free survival relative to historical controls in patients with Unresectable or Metastatic Undifferentiated Pleomorphic Sarcoma.
- Trial name
- NCT03946943
- Testing
- Anlotinib, Toripalimab, Blood Draw
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Di Wu